Compare VOD & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VOD | ONC |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | United Kingdom | Switzerland |
| Employees | 86702 | 12000 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.1B | 33.5B |
| IPO Year | N/A | N/A |
| Metric | VOD | ONC |
|---|---|---|
| Price | $14.72 | $283.68 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | N/A | ★ $377.91 |
| AVG Volume (30 Days) | ★ 3.5M | 242.6K |
| Earning Date | 11-14-2025 | 05-06-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.65 | $759.19 |
| Revenue Next Year | $5.40 | $14.51 |
| P/E Ratio | ★ N/A | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.05 | $196.53 |
| 52 Week High | $15.91 | $385.22 |
| Indicator | VOD | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 35.73 |
| Support Level | $14.56 | $239.25 |
| Resistance Level | $14.81 | $284.51 |
| Average True Range (ATR) | 0.25 | 6.68 |
| MACD | -0.00 | -0.50 |
| Stochastic Oscillator | 86.29 | 29.74 |
Vodafone operates mobile and fixed-line networks and businesses across Europe, Africa, and the Middle East. Its largest market is Germany, where it is the second mobile operator after Deutsche Telekom and owns two cable network after acquiring Kabel Deutschland in 2013 and Liberty Global Germany in 2019. In the UK Vodafone merger with CK Hutchison in 2024, consolidating the mobile market. It also divested its Spanish and Italian divisions in that same year, given their low returns on invested capital.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.